Interpace Biosciences, Inc. (IDXG) Stock Price & Analysis
Interpace Biosciences, Inc. (IDXG) — price $4.60 (-15.29%), as of the Nov 19, 2026 trading session; market cap $27.2M.
Educational signal · not a buy or sell recommendation · How to read this
Interpace Biosciences, Inc. · IDXG
Interpace Biosciences, Inc. specializes in molecular diagnostic tests, bioinformatics, and pathology services, primarily focusing on evaluating cancer risk in the United States. The company offers a suite of proprietary genomic tests for pancreatic, thyroid, and lung cancers, serving physicians, hospitals, and clinics.
Price as of Nov 19, 2026
Key Statistics
No MoonshotScore yet: we have not published a score for this company.
Thousands of the 20,000+ US stocks here carry a MoonshotScore.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $4.60 | |
| Change on the day | -15.29% | |
| Market capitalisation | $27.2M | — |
| Price / earnings (trailing) | 0.23 | |
| Shares traded on the day | 5.7K |
Price & events
Other perspectives
Council score for Interpace Biosciences (IDXG): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 11, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Interpace Biosciences (IDXG), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Interpace Biosciences, Inc. (IDXG) is the company analyzed here. It employs 102 people. In Q2 FY2026 it reported revenue of $9M and net income of $158,000. The market values it at $27.2M.
What do the latest results show for Interpace Biosciences (IDXG)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $9M. Against analyst estimates the company has EPS beat 6 of the last 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $9M | $158,000 | $0.03 (diluted) |
| Q1 FY2026 | $9M | $721,000 | $0.13 (diluted) |
| Q4 FY2025 | $9M | $23M | $4.10 (diluted) |
| Q3 FY2025 | $9M | $911,000 | $0.16 (diluted) |
What are the financial strengths and risks for Interpace Biosciences (IDXG)?
Short answer · as of
The distress and quality screens read Altman Z -4.96 · Piotroski F 5. Trailing ratios: ROE 143.0% · ROA 70.8% · current ratio 2.22 · earnings yield 71.2% · free-cash-flow yield 11.2%.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held IDXG in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported IDXG in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Common Questions About IDXG
These answers are editorial: 1 of these 8 answers is drawn from the IDXG research dossier (written Jun 15, 2026 by gemini-2.5-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is IDXG a good stock to buy?
Stock Expert AI does not rate IDXG buy, sell or hold. Interpace Biosciences, Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the IDXG stock price today?
The last price recorded for Interpace Biosciences, Inc. (IDXG), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are Interpace Biosciences' primary diagnostic offerings and their applications?
Interpace Biosciences, Inc. specializes in a suite of molecular diagnostic tests for cancer risk assessment. Key offerings include PancraGEN, a genomic test for pancreatic cysts and lesions, which utilizes the PathFinderTG platform to assess cancer risk.
What are the key factors to evaluate for IDXG?
Evaluate IDXG on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. Not financial advice.
How frequently does IDXG data refresh on this page?
IDXG's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven IDXG's recent stock price performance?
Interpace Biosciences, Inc. (IDXG) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary and specialized molecular diagnostic tests for various cancers (pancreatic, thyroid, lung). See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider IDXG overvalued or undervalued right now?
The trailing P/E of Interpace Biosciences, Inc. (IDXG) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research IDXG before investing?
Before investing in Interpace Biosciences, Inc. (IDXG), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 13 figures on this page — 9 from Financial Modeling Prep (FMP) and 4 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com